Scientists have long grappled with the monumental challenge of treating genetic disorders caused by a bewildering array of mutations scattered across genes. Traditional genome editing techniques focus on correcting individual mutations, an approach that becomes painstakingly complex and impractical when faced with the sheer diversity of mutations within a single gene. To rethink this paradigm, researchers from Mass General Brigham have pioneered a transformative method that bypasses mutation-specific corrections entirely by enabling the precise insertion of entire gene-sized DNA sequences into predetermined genomic locations.
In a landmark study published in Nature, the team unveiled INSTALL, a novel technology that harnesses the stealth capabilities of single-stranded DNA circles to evade the immune system’s vigilant defenses — a major barrier thwarting previous large-scale genome integration attempts. Classical methods employing double-stranded DNA (dsDNA) donors have often triggered robust immune responses, resulting in toxicities that cap the dosage and hamstring therapeutic application, especially in vivo. Viruses as delivery vectors, while useful, present safety concerns and elevated costs, making non-viral and non-toxic strategies highly sought after.
The crux of INSTALL’s innovation lies in its refined design of DNA donors as circles predominantly composed of single-stranded DNA (ssDNA), armed with short double-stranded segments strategically incorporated to facilitate recognition and function by recombinase enzymes. This clever hybrid structure retains the immune evasiveness characteristic of ssDNA, while concurrently permitting recombinase-mediated insertion — a feat previously hindered by the enzymes’ natural affinity for double strands. By emulating bacterial and bacteriophage strategies, which inherently resolve similar integration conundrums, the team harnessed evolutionary wisdom to engineer this new genome writing platform.
Benjamin P. Kleinstiver, PhD, senior author and investigator at the Center for Genomic Medicine, explained that this approach potentially paves the way for “moving beyond the treatment of single mutations at a time,” hinting at a future where a single genetic payload could replace multiple unique mutations associated with disease. The dual challenge of immunogenicity and functional compatibility has been elegantly surmounted, marking a revolutionary stride in genome engineering that could democratize gene therapies.
Lead author Connor Tou, PhD, recounted the initial excitement of observing the immune system’s subdued reaction to the INSTALL DNA donors: “When the INSTALL-treated mice looked similar to untreated controls, we knew this could be a game changer.” This milestone is critical because immune-mediated toxicities have been a persistent obstacle in gene therapy, often leading to fatal outcomes in animal models and raising serious concerns for human applications.
The team’s research involved rigorous experimental validation in diverse human cell types, demonstrating that INSTALL can seamlessly integrate large genetic sequences without eliciting the deleterious immune activation associated with traditional double-stranded DNA donors. Progressing from petri dishes to live organisms, they utilized lipid nanoparticles (LNPs) to deliver these DNA circles and recombinase enzymes into mice. Significantly, the mice not only tolerated the treatment well but exhibited successful genomic incorporation in liver cells, underscoring INSTALL’s versatility and clinical potential.
This non-viral delivery method addresses another critical limitation in genome editing. Viral vectors, such as adeno-associated viruses (AAVs), carry inherent constraints related to production scalability, pre-existing immunity in patients, and insertional mutagenesis risks. INSTALL’s LNP-mediated transfer opens doors to scalable, safer, and cost-effective gene therapies that can be administered repeatedly or systemically without provoking harmful immune reactions.
Furthermore, the method’s ability to insert kilobase-sized DNA sequences — encompassing entire functional genes or large regulatory regions — vastly expands the scope of genome engineering applications. By equipping recombinases with the capability to work alongside these custom-designed DNA donors, the research team effectively grants genome writers a new language for editing — one that is both sophisticated and compatible with human cellular machinery.
The cross-disciplinary collaboration underlying this breakthrough was extensive, involving expertise from Full Circles Therapeutics in manufacturing and commercializing circular single-stranded DNA (cssDNA), and contributions from leading genomic medicine and bioengineering laboratories. Such synergy highlights the importance of integrating molecular biology, immunology, synthetic biology, and nanotechnology to overcome entrenched barriers in gene therapy development.
Looking ahead, the researchers are optimistic that refining both the DNA cargo constructs and the recombinase enzymes will further optimize the efficiency, specificity, and safety of INSTALL. This trajectory promises to accelerate the translation of gene writing technologies into broadly applicable treatments that could alleviate the burden of myriad genetic diseases with a single, universal intervention.
Ultimately, this pioneering work signifies a paradigm shift in how we approach the genomic correction of complex diseases. By sidestepping the need for mutation-specific edits and circumventing immune system triggers, INSTALL heralds a new era where large-scale genome rewriting is not just conceivable, but feasible and practical. It is a leap forward that resonates far beyond laboratories, promising to redefine therapeutic strategies for countless patients worldwide.
Subject of Research: Cells
Article Title: Immune evasive DNA donors and recombinases license kilobase-scale writing
News Publication Date: 11-Mar-2026
Web References:
https://www.nature.com/articles/s41586-026-10241-z
http://dx.doi.org/10.1038/s41586-026-10241-z
References:
Tou C et al. “Immune evasive DNA donors and recombinases license kilobase-scale writing” Nature DOI: 10.1038/s41586-026-10241-z
Keywords
Targeted genome editing, Genome engineering, Genome editing, CRISPRs, Gene editing, Gene therapy, Genetic material, DNA.
